Pfizer ADC Adcetris gains additional lymphoma indication

New York during the COVID-19 emergency.

Massimo Giachetti

  • The U.S. FDA has granted an additional approval for Pfizer’s (NYSE:PFE) antibody-drug conjugate Adcetris (brentuximab vedotin), this time for large B-cell lymphoma (LBCL).
  • The new indication is specifically as a third-line therapy for those ineligible for autologous hematopoietic stem cell

Leave a Reply

Your email address will not be published. Required fields are marked *